News & Events

• May 20, 2021
  

  The Role of Patient-reported Outcomes and Medication Adherence Assessment in Patient-focused Drug Development for Solid Organ Transplantation

• April 21, 2020
  

  Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: the 2019 Expert Consensus From the Transplant Society Working Group

• February 24, 2020
  

  Use of Biomarkers to Improve Immunosuppressive Drug Development and Outcomes in Renal Organ Transplantation: A Meeting Report

• October 9, 2019
  

  On September 25th, the FDA published a Personal Viewpoint in the American Journal of Transplantation

  This Personal Viewpoint is in response to a whitepaper published by the TTC titled “The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients”.

  This article provides a FDA perspective on the whitepaper, the overall TTC effort, and public-private partnerships with authors from the Office of New Drugs, Office of Translational Sciences, and Clinical Outcome Assessment staff in CDER.

• March 19, 2019
  

  The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients